New B Cell Therapy Shows Striking Power Against Neuromyelitis Optica
A phase III trial of obinutuzumab β shows striking efficacy in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, deepening questions about which ...
A phase III trial of obinutuzumab β shows striking efficacy in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, deepening questions about which ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine